FinCanna Capital Corp., the royalty investment company for licensed medical cannabis, and Astar Minerals Ltd. (TSX VENTURE: TAR) reports that FinCanna’s flagship investment, Cultivation Technologies, Inc. (CTI), has begun operations in Coachella, California with one of the state’s first permitted solvent extraction facilities for medical cannabis.
CTI established the medical cannabis extraction lab as an interim facility in accordance with its conditional use permit in Coachella. The lab will remain in operation during the construction of the full 6-acre medical cannabis campus planned for the site.
CTI reported that its extraction tenant, Not My Extractsis now producing raw oil, various concentrates and other medical cannabis products for leading brands, including Living Extracts™ (a featured brand on WeedMaps®) and CTI’s first exclusive brand, Coachella Premium™. Not My Extracts is also providing extraction-as-a-service.
CTI, an emerging leader in medical cannabis infrastructure, genetics, technology, and branding, has enabled Not My Extracts’ operations by providing access to a fully-permitted facility, operating capital and equipment financing. CTI is contracted to receives fees from Not My Extracts in exchange for its support, as well as licensing fees for production of CTI brands.
“After months of development and working closely with local government leaders, CTI has now officially entered its operational phase with a very capable producer,” said CTI co-founder and chief strategy officer, Justin Beck, in a press release CTI issued today. “The opening of this facility enables the commercialization of Coachella Premium, CTI’s exclusive ultra-premium medical cannabis brand.”
According to CTI, Not My Extracts is now positioned to become a leading white-label producer for brands throughout California, most of which do not have access to compliant production. Select medical cannabis brands produced at the CTI Coachella campus will be able to leverage an integrated production, marketing, and distribution platform as part of operational collaborations with Not My Extracts.
“CTI has quickly become a leader in California’s cannabis industry with its extraordinary leadership team and successful legislative efforts,” said Christopher Thayer, founder of Not My Extracts. “We couldn’t have chosen a better partner for this endeavor.”
“We would also like to thank the City of Coachella and Riverside Fire Department for their diligence and support,” added Thayer. “We look forward to serving the immediate and future needs for leading brands in California including Coachella Premium.”
While the lab is among the first medical cannabis solvent extraction facilities to be legally permitted in California, CTI believes it to be the first such facility to conform to California’s AB 2679, a key CTI-sponsored legislation passed in 2016 allowing locally-permitted extraction labs to operate legally.
“We’ve been impressed by the tremendous progress CTI has been making in terms of both operational development and organization of an exceptional management team and board of directors,” said Andriyko Herchak, president and CEO of FinCanna Capital. “Their efforts have culminated in today’s major milestone, which is paving the way toward future growth and expansion as a leader in California’s medical cannabis industry.”
About Cultivation Technologies
Cultivation Technologies, Inc. provides infrastructure, genetics, technology, and branding to the legal medical cannabis industry. The first major project for the company is in Coachella, California, which will span 6-acres featuring cultivation centers, manufacturing facilities, a testing lab, a distribution hub, and a centralized processing center. For more information, visit www.CultivationTech.com.
About Not My Extracts
Not My Extracts is a California non-profit mutual benefit corporation formed under “collective law,” a requirement for legal operations in 2017. Pursuant to AB 2679, all volatile solvent extraction is conducted within closed-looped systems with engineer-certified equipment and fire department approvals, among other requirements.
About FinCanna Capital Corp.
FinCanna, is a royalty investment company for licensed medical cannabis, with a focus on California. FinCanna, led by a team of finance and industry experts is building its portfolio of investments in scalable, best-in-class projects. FinCanna’s flagship investment is with Cultivation Technologies, Inc. (CTI) to provide funding for its fully-entitled, large-scale indoor medical cannabis facility to be developed in Coachella, Southern California. This Coachella Campus will be a state-of-the-art facility that will include cultivation, extraction, manufacturing, testing and distribution. For additional information visit www.fincannacapital.com.
FinCanna and Astar entered into a binding agreement on July 13, 2017, pursuant to which Astar will acquire all of the issued and outstanding common shares of FinCanna on a one for one basis (the “Transaction”).
All trademarks in this press release are the exclusive property of their respective owners.
Neither the TSX Venture Exchange or the CSE in any way passed upon the merits of the Transaction and has neither approved nor disapproved the contents of this news release.
This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
All information contained in this news release with respect to Astar and FinCanna was supplied by the parties, respectively, for inclusion herein, and each parties’ directors and officers have relied on the other party for any information concerning such party.
Forward-Looking Information
This news release contains forward-looking information based on current expectations. Statements about, among other things, the closing of the Transaction and the future business plans and prospects of CTI are forward looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such factors include, but are not limited to: the parties’ ability to satisfy various closing conditions of the Transaction, including receipt of all regulatory and shareholder approvals and the ability of CTI to execute on its current business plan. Although such statements are based on management’s reasonable assumptions at the date such statements are made, there can be no assurance that the Transaction will occur or that, or if the Transaction does occur, it will be completed on the terms described above and that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on the forward-looking information. Astar and FinCanna assume no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.
CONTACT INFORMATION

Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less

CFN Enterprises Inc. (OTCQB: CNFN) (CFN Media) partners with FMW Media Works LLC to produce a regular series on the global cannabis markets to air on major financial news networks across the US. Initial segment features leading cannabis analyst and US Multi-State Operator (MSO)

CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced that its inaugural news segment on the cannabis markets, “Cannabis Market Outlook for 2021,” will air on Bloomberg, Newsmax and Fox Business.

Keep reading... Show less